Insulet Launches Omnipod 5 Update with New Target Glucose Option

Insulet Corporation (NASDAQ:PODD) announced on June 3 the launch of significant enhancements to its Omnipod 5 Automated Insulin Delivery (AID) System in the United States, featuring a new 100 mg/dL Target Glucose option. The update aims to offer greater personalization and improved glycemic control, allowing users to spend more time in their target glucose range.

The Product

The Omnipod 5 system is the first tubeless hybrid closed-loop system approved by the U.S. FDA. The new update adds a 100 mg/dL target glucose option to the existing range (110, 120, 130, 140, 150 mg/dL), providing users with more flexibility to achieve tighter glycemic targets.

Pricing and Availability

The update is currently available to existing Omnipod 5 users in the US via a free software update to the mobile app. Insulet has not announced any changes to pricing.

Competition

Insulet faces competition from Medtronic (MDT) with its MiniMed 780G system and Tandem Diabetes Care (TCMD) with Control-IQ. However, Omnipod 5's tubeless design offers a convenience advantage.

Potential Impact on the Company

This enhancement is expected to strengthen Insulet's position in the automated insulin delivery market, particularly among patients seeking tighter glucose control. It could lead to increased market share and higher revenue from consumable sales.